Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(25)00362-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CRISPR-engineered T-cell therapies: some clarifications needed - Authors' reply.
Lancet Oncol
August 2025
Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA.
CRISPR-engineered T-cell therapies: some clarifications needed.
Lancet Oncol
August 2025
Western (Chongqing) Collaborative Innovation Center for Intelligent Diagnostics and Digital Medicine, Chongqing, 401329, China. Electronic address:
CRISPR-engineered T-cell therapies: some clarifications needed.
Lancet Oncol
August 2025
Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32608, USA. Electronic address:
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.
Biomark Res
May 2025
Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Head and neck squamous cell carcinoma (HNSCC) remains among the most aggressive malignancies with limited treatment options, especially in recurrent and metastatic cases. Despite advances in surgery, radiotherapy, chemotherapy, and immune checkpoint inhibitors, survival rates remain suboptimal due to tumor heterogeneity, immune evasion, and treatment resistance. In recent years, Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized hematologic cancer treatment by genetically modifying T cells to target tumor-specific antigens like CD19, CD70, BCMA, EGFR, and HER2, leading to high remission rates.
View Article and Find Full Text PDFModulation of TCR stimulation and pifithrin-α improve the genomic safety profile of CRISPR-engineered human T cells.
Cell Rep Med
December 2024
Technical University of Munich (TUM), School of Medicine and Health, Department of Preclinical Medicine, Institute for Medical Microbiology, Immunology and Hygiene, 81675 Munich, Germany; TUM, Institute for Advanced Study, 85748 Garching, Germany. Electronic address:
Article Synopsis
- - CRISPR-engineered CAR T cells show promise in cancer treatments but have been linked to chromosomal issues due to the CRISPR process.
- - The study reveals that increased T cell activation and faster proliferation lead to larger DNA deletions, while non-activated T cells have a lower risk but are less effective for gene editing.
- - A small molecule called pifithrin-α can reduce chromosomal damage while preserving the functionality of CRISPR-engineered T cells, making it a viable strategy for improving genomic safety.